Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status
Tofacitinib is an oral, small-molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We summarize the efficacy and safety data of tofacitinib 5 or 10 mg twice daily in the UC clinical program, stratified by prior tumor necrosis factor inhibitor (TNFi) failure status.Efficacy w...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | 英语 |
| 出版: |
2021
|
| 在線閱讀: | https://doi.org/10.1016/j.cgh.2021.02.043 http://www.cghjournal.org/article/S1542356521002226/pdf |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|